The government are to scrap repeat assessments of people claiming ESA (Employment Support Allowance) if they have a condition that is unlikely to have improved.
Siponimod reduced the risk of progression in secondary progressive MS (SPMS) according to results presented at the ECTRIMS meeting in London on 17 September.
A new report from the MS Trust shows that two in three people with MS in the UK live in areas where there aren’t enough MS nurses to provide vital care and support.
Initial research results suggest siponimod may slow progression in people with secondary progressive MS
The Patient Information Forum (PIF) are looking for people living with MS who may be interested in taking part in a focus group for its ‘perfect information journey’ project focused on improving access to information for patients with long-term conditions.
People experiencing the first signs and symptoms of neurological conditions like MS are waiting too long to see an appropriate specialist, according to over 1,000 GPs surveyed across the UK.
A government report published today recommends that everyone should aim to consume 10 micrograms of vitamin D (400 IU) each day to ensure healthy bones and muscles.
The European Commission (EC) has granted marketing authorization for daclizumab (Zinbryta) for the treatment of adults with relapsing forms of multiple sclerosis. This follows a recommendation from the European Medicines Agency in May that a licence should be granted.
A national survey of people living with a neurological condition, including multiple sclerosis, launches today. The Neurological Alliance, representing 80 organisations working across England to improve life for people living with a neurological condition, is running their second neurological patient experience survey.